Experimental studies in H22 tumor-bearing models and orthotopic HCC models revealed that this nanosystem leverages enhanced glypican-3 (GPC3) and tumor vascular cell adhesion molecule-1 (VCAM1) targeting to recognize and capture CTCs. This evidence concerns the gene GPC3 and neoplasm.